meta
|
evidence
oncology
Living systematic review and meta-analysis
metastatic/advanced mGC or mGEJC
mGC or mGEJC - 1st line (L1)
mGC or mGEJC - L1 - all population
mGC or mGEJC - L1 - HER2 neg/PDL1 positive
2
mGC or mGEJC - L1 - HER2 negative
1
mGC or mGEJC - L1 - HER2 positive
mGC or mGEJC - L1 - PDL1 positive
4
mGC or mGEJC - 2nd Line (L2)
mGC or mGEJC - L2 - all population
4
mGC or mGEJC - L2 - PDL1 positive
1
mGC or mGEJC - maintenance (M)
mGC or mGEJC - M - HER2 negative
1
mGC or mGEJC - M - HER2 neg/PDL1 positive
1
gene alteration defined cancer
immune chekpoint inhibitors
anti-PD-(L)1
pembrolizumab based treatment
pembrolizumab alone
pembrolizumab plus SoC
versus all
vs chemotherapy
vs Standard of Care (SoC)
vs placebo plus SoC
study list
mapping
overview
meta-analysis
forest plot
NMA
excluded
graph
EGM
comparisons
Top evidence (RCT only, high risk of bias excluded)
Best available evidence (possibly low or very low)
All RCTs
All studies (RCT+OBS)
pembrolizumab alone
title
placebo plus SoC
title
Standard of Care (SoC)
title
KEYNOTE-062 (P vs C ; CPS>10), 2020 NCT02494583 mGC or mGEJC - L1 - PDL1 positive 92/90
KEYNOTE-062 (P vs C ; CPS>1), 2020 NCT02494583 mGC or mGEJC - L1 - PDL1 positive 256/250
Pathology:
mGC or mGEJC - L1 - PDL1 positive;
mGC or mGEJC - L1 - PDL1 positive
KEYNOTE-062 (P vs C ; CPS>10), 2020
KEYNOTE-062 (P vs C ; CPS>1), 2020
pembrolizumab alone
2
T1
T1
placebo plus SoC
0
T0
Standard of Care (SoC)
0
T0